KalVista Data at 2023 HAEi Regional Conference EMEA

 KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting taking place in Munich, Germany from September 1-3. KalVista is a Silver-level sponsor of the meeting. The presentations are:

• In Their Own Words - Patient Descriptions of the Earliest Recognition of HAE Attack Onset: Michael E. Manning, Autumn F. Burnette, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Mar Guilarte, Anna Valerieva (presenter only). Results shared as a poster presentation and Q&A

• Recognizing the Importance of Early On-Demand Treatment in the HAE Attack Journey: Douglas H. Jones, Princess Ogbogu, Sally van Kooten, Markus Heckmann, Sherry Danese, Ledia Goga, Markus Magerl (presenter). Results shared as a poster presentation and Q&A

All poster presentations will take place on Friday, September 1 starting at 7:15 p.m. CEST in the Foyer on the 1st floor of the Westin Grand Hotel.

KalVista will also be launching a new patient-focused site called “Mind the HAE Attack” at HAEi EMEA on September 1. Mind the HAE Attack has been developed with the HAE community to address the psychological and physical burdens of HAE attacks, and to create tools that support treatment at the onset of an attack. You can find the site at MindtheHAEattack.com.

https://www.biospace.com/article/releases/kalvista-pharmaceuticals-to-present-hae-attack-journey-data-at-2023-haei-regional-conference-emea/